Ishibashi Mariko, Takahashi Miwako, Yamaya Taiga, Imai Yoichi
Department of Microbiology and Immunology, Nippon Medical School, Tokyo 113-8602, Japan.
Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
Life (Basel). 2023 Aug 7;13(8):1701. doi: 10.3390/life13081701.
Positron emission tomography (PET) is an imaging modality used for the noninvasive assessment of tumor staging and response to therapy. PET with F labeled fluorodeoxyglucose (F-FDG PET) is widely used to assess the active and inactive lesions in patients with multiple myeloma (MM). Despite the availability of F-FDG PET for the management of MM, PET imaging is less sensitive than next-generation flow cytometry and sequencing. Therefore, the novel PET radiotracers Cu-LLP2A, Ga-pentixafor, and Zr-daratumumab have been developed to target the cell surface antigens of MM cells. Furthermore, recent studies attempted to visualize the tumor-infiltrating lymphocytes using PET imaging in patients with cancer to investigate their prognostic effect; however, these studies have not yet been performed in MM patients. This review summarizes the recent studies on PET with F-FDG and novel radiotracers for the detection of MM and the resulting preclinical research using MM mouse models and clinical studies. Novel PET technologies may be useful for developing therapeutic strategies for MM in the future.
正电子发射断层扫描（PET）是一种用于肿瘤分期和治疗反应无创评估的成像方式。氟代脱氧葡萄糖（F-FDG）PET被广泛用于评估多发性骨髓瘤（MM）患者的活性和非活性病灶。尽管F-FDG PET可用于MM的管理，但PET成像的敏感性低于新一代流式细胞术和测序。因此，已开发出新型PET放射性示踪剂Cu-LLP2A、Ga-喷替沙氟和Zr-达雷妥尤单抗来靶向MM细胞的细胞表面抗原。此外，最近的研究试图利用PET成像在癌症患者中可视化肿瘤浸润淋巴细胞，以研究其预后作用；然而，这些研究尚未在MM患者中进行。本综述总结了近期关于F-FDG PET和新型放射性示踪剂用于检测MM的研究，以及由此产生的使用MM小鼠模型的临床前研究和临床研究。新型PET技术未来可能有助于制定MM的治疗策略。
